Related Experiment Videos
[The therapeutic effectiveness of chestnut extract]
1Abteilung für Klinische Pharmakologie, I. Medizinische Universitätsklinik, Wien.
Wiener Medizinische Wochenschrift (1946)
|September 15, 1989
Summary
Venostasin ret. effectively treats chronic venous insufficiency by improving vein tone and reducing swelling. This well-tolerated medication offers proven therapeutic benefits for patients experiencing venous disorders.
Area of Science:
- Pharmacology
- Phlebology
- Biochemistry
Background:
- Chronic venous insufficiency (CVI) is characterized by impaired venous tone and increased vascular permeability.
- Lysosomal enzymes play a role in the pathophysiology of CVI, contributing to tissue damage.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Venostasin ret. in patients with CVI.
- To investigate the pharmacological effects of Venostasin ret. on the venous system.
Main Methods:
- Multiple pharmacological, clinical pharmacological, and clinical investigations were conducted.
- Double-blind, randomized, cross-over studies assessed subjective complaints and objective measures like edema.
- Biometrical investigations confirmed clinical effectiveness.
Main Results:
- Venostasin ret. demonstrated tonical effects on veins, reduced permeability, and provided protective/curative properties.
- Significant reduction in subjective complaints was observed.
- Objective improvements in edema were confirmed through biometrical analysis.
Conclusions:
- Venostasin ret., standardized to 50 mg triterpenglycosides (escine), is therapeutically effective for chronic venous insufficiency.
- The drug exhibits good tolerability, supporting its recommendation for CVI treatment.
- Further research into the biochemical mechanisms, particularly lysosomal enzyme attenuation, is warranted.